Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—som…
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KR
Read Full Story at ScienceDaily →Why This Matters
The breakthrough in targeting KRAS—long considered an "undruggable" mutation—represents a paradigm shift in oncology, proving that even the most aggressive cancers can be outmaneuvered with precision medicine. Beyond pancreatic cancer, this development validates a new class of inhibitors that could unlock treatments for other KRAS-driven tumors, reshaping the future of targeted cancer therapy.
Background Context
Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, has evaded drug development for decades due to its complex tumor microenvironment and the elusive nature of KRAS mutations. Historically, KRAS was deemed untargetable, forcing patients into brutal chemotherapy regimens with dismal survival rates. The FDA’s accelerated approval pathway has now accelerated the shift toward molecularly tailored therapies.
What Happens Next
Clinical trials will expand to refine dosing, assess combination therapies, and identify biomarkers for patient selection, potentially turning a niche drug into a standard of care. Regulators and insurers will face pressure to balance breakthrough pricing with equitable access, while researchers race to apply KRAS-inhibitor strategies to colon, lung, and other solid tumors.
Bigger Picture
This milestone underscores the accelerating pace of genomic medicine, where once-fatal mutations are increasingly yielding to structural biology and computational drug design. It also highlights a growing divide between cancers with actionable targets and those still reliant on older, less effective treatments—a gap that could deepen disparities in oncology care.
